RxDoctor Payments Data

Wayne Evancho, DO

Family Medicine · North Miami Beach, FLNPI 1619069804

Payments from drug & device makers

$351in general payments, 2019–2025

Across 21 payments — averaging $16.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sunovion Pharmaceuticals Inc.$116
  • GSK$63
  • Novartis$45
  • Abbott$41
  • Cipher Pharmaceuticals US LLC$28
  • Johnson & Johnson$22
  • plus $35 from 2 others

What the payments were for

  • Food & beverage$351100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Sunovion Pharmaceuticals Inc.9$116
GSK3$63
Novartis2$45
Abbott2$41
Cipher Pharmaceuticals US LLC1$28
Johnson & Johnson2$22
Lilly USA, LLC1$18
Pfizer1$17

How this compares

$351 in reported general payments places this provider in the 40th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$279,742
Medicare patients
406
Services billed
2,767

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban425$169,782
TrulicityDulaglutide90$75,632
XareltoRivaroxaban148$66,970
IngrezzaValbenazine Tosylate11$43,278
JanuviaSitagliptin Phosphate52$41,330
OzempicSemaglutide38$36,467
EntrestoSacubitril/Valsartan37$35,965
ProcritEpoetin Alfa47$32,946
LinzessLinaclotide25$19,585
AptiomEslicarbazepine Acetate26$16,685
FarxigaDapagliflozin Propanediol16$15,262
Trelegy ElliptaFluticasone/Umeclidin/Vilanter16$14,389
JardianceEmpagliflozin11$12,587
TradjentaLinagliptin18$12,074
Potassium Chloride333$10,747

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$17$169,782425 claims
Johnson & JohnsonXarelto, Procrit$22$99,916195 claims
Lilly USA, LLCTrulicity$18$75,63290 claims
NovartisEntresto$45$35,96537 claims
GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta$63$28,33250 claims
Sunovion Pharmaceuticals Inc.Aptiom$116$16,68526 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 7,282 family medicine providers in Florida.

Other family medicine in North Miami Beach

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →